2022
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
Auteurs:
Ferrari-Souza, J.P., Ferreira, P.C.L., Bellaver, B., Tissot, C., Wang, Y.T., Leffa, D.T., Brum, W.S., Benedet, A.L., Ashton, N.J., De Bastiani, M.A., Rocha, A., Therriault, J., Lussier, F.Z., Chamoun, M., Servaes, S., Bezgin, G., Kang, M.S., Stevenson, J., Rahmouni, N., Pallen, V.**, Poltronetti, N.M., Klunk, W.E., Tudorascu, D.L., Cohen, A., Villemagne, V.L., Gauthier, S.*, Blennow, K., Zetterberg, H., Souza, D.O., Karikari, T.K., Zimmer, E.R., Rosa-Neto, P.*, Pascoal, T.A.
Revue:
MedRxiv
Abstract
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([18F]AZD4694) and tau ([18F]MK6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of Aβ and tau, respectively, on hippocampal atrophy, ultimately leading to cognitive impairment. Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain Aβ and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.
Partager
Recevez les
dernières nouvelles
Suivez les derniers développements de la recherche au sein du CCNA-CCNV. Notre section «Nouvelles» fournit des informations sur les études, les avancées et les principaux résultats de la recherche en matière de santé cérébrale.
